Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines.
Year: 2010
Type: article
Source: PubMed
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Cancer Institute
OpenAlex ID: W2243411380
